Lancet Oncology

Published by: Elsevier Science, Inc.  

People

  1. Drilon
    Drilon
  2. Ladanyi
    Ladanyi
  3. Capanu
    Capanu
  4. Chi
    Chi
  5. Chou
    Chou
  6. Gonen
    Gonen
  7. Hakimi
    Hakimi
  8. Ilson
    Ilson
  9. Janjigian
    Janjigian
  10. Kuo
    Kuo

Groups

  1. GSK Faculty (15)
  2. Human Oncology and Pathogenesis Program (15)
  3. Department of Medicine (13)
  4. Solid Tumor Oncology Division (12)
  5. Biostatistics Service (6)
  6. Epidemiology and Biostatistics (6)
  7. Tow Center for Developmental Oncology (TCDO) (6)
  8. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (5)
  9. Department of Pathology and Laboratory Medicine (5)
  10. Surgery (5)
Search Within
  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (13)
  2. Review (2)
Groups
  1. GSK Faculty (15)
  2. Human Oncology and Pathogenesis Program (15)
  3. Department of Medicine (13)
  4. Solid Tumor Oncology Division (12)
  5. Biostatistics Service (6)
  6. Epidemiology and Biostatistics (6)

More Groups

People
  1. Alexander Drilon (3)
  2. Marc Ladanyi (3)
  3. Abraham Hakimi (2)
  4. David Ilson (2)
  5. David Solit (2)
  6. Fengshen Kuo (2)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (2)
  4. 2022 (1)
  5. 2020 (4)
  6. 2018 (1)

More Years

Publishers
  1. Elsevier Science, Inc. (15)

Results (15)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: A first-in-human, single-centre, phase 1 trial
    Journal Article

    Lou, E.; Choudhry, M. S.; Starr, T. K.; Folsom, T. D.; Bell, J.; Rathmann, B.; DeFeo, A. P.; Kim, J.; Slipek, N.; Jin, Z.; more...
    Lancet Oncology (2025)

    Fulltext@MSK | Save
  • Interpretable artificial intelligence to optimise use of imatinib after resection in patients with localised gastrointestinal stromal tumours: An observational cohort study
    Journal Article

    Bertsimas, D.; Margonis, G. A.; Sujichantararat, S.; Koulouras, A.; Ma, Y.; Antonescu, C. R.; Brennan, M. F.; Martín-Broto, J.; Tang, S.; Rutkowski, P.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer
    Review

    Browne, I. M.; André, F.; Chandarlapaty, S.; Carey, L. A.; Turner, N. C.
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: A single-arm, single-centre, phase 2 trial
    Journal Article

    Cytryn, S. L.; Moy, R. H.; Cowzer, D.; Shah, R. H.; Chou, J. F.; Joshi, S. S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: Challenges and recommended priorities
    Review

    Kim, M. M.; Mehta, M. P.; Smart, D. K.; Steeg, P. S.; Hong, J. A.; Espey, M. G.; Prasanna, P. G.; Crandon, L.; Hodgdon, C.; Kozak, N.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: A retrospective study and meta-analysis
    Journal Article

    Ecker, B. L.; Lee, J.; Saadat, L. V.; Aparicio, T.; Buisman, F. E.; Balachandran, V. P.; Drebin, J. A.; Hasegawa, K.; Jarnagin, W. R.; Kemeny, N. E.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): A double-blind, randomised, placebo-controlled, phase 3 trial
    Journal Article

    Blay, J. Y.; Serrano, C.; Heinrich, M. C.; Zalcberg, J.; Bauer, S.; Gelderblom, H.; Schöffski, P.; Jones, R. L.; Attia, S.; D'Amato, G.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: An open-label, single-arm, phase 2 trial
    Journal Article

    Janjigian, Y. Y.; Maron, S. B.; Chatila, W. K.; Millang, B.; Chavan, S. S.; Alterman, C.; Chou, J. F.; Segal, M. F.; Simmons, M. Z.; Momtaz, P.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1/2 clinical trials
    Journal Article

    Hong, D. S.; DuBois, S. G.; Kummar, S.; Farago, A. F.; Albert, C. M.; Rohrberg, K. S.; van Tilburg, C. M.; Nagasubramanian, R.; Berlin, J. D.; Federman, N.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: A cohort study
    Journal Article

    Sanchez, A.; Furberg, H.; Kuo, F.; Vuong, L.; Ged, Y.; Patil, S.; Ostrovnaya, I.; Petruzella, S.; Reising, A.; Patel, P.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save

    • Lancet Oncology – authorized name for:

    Name ISSN / ISBN Publisher
    Lancet Oncology 1470-2045 Elsevier Science, Inc.
    Lancet Oncology 1470-2045 The Lancet Publishing Group
    Lancet Oncology 1470-2045 Elsevier B.V.
    Lancet Oncology 1470- Elsevier Science, Inc.
    Lancet Oncology 14702045 Elsevier Science, Inc.
    Lancet Oncology 1470-2045 Elsevier Inc.
    Lancet Oncology 14702045 Elsevier Science, Inc.
    Lancet Oncology 1470-2045 Elsevier Science, Inc.
    Lancet Oncology 1470-2045 Elsevier Inc.
    Lancet Oncology 1470-2045 Elsevier Science, Inc.
    Lancet Oncology 1470-2045 Elsevier Science, Inc.
    Lancet Oncology 0094-0143 Unknown
    Lancet Oncology 0732-183X Unknown
    Lancet Oncology 1089-9472 Unknown
    Lancet Oncology 0938-7994 Unknown
    Lancet Oncology 2314-6133 Unknown
    Lancet Oncology 2152-2650 Unknown
    Lancet Oncology 1471-2407 Unknown
    Lancet Oncology 1470-2045 Elsevier Science, Inc.
    Lancet Oncology 1470-2045 Unknown
    Lancet Oncology 1470-2045 The Lancet Publishing Group
    Lancet Oncology 14702045 Elsevier Inc.
    Lancet Oncology 14702045 Unknown
    The Lancet Oncology 1470-2045 Elsevier Science, Inc.
    The Lancet Oncology 14745488 Elsevier Inc.
    The Lancet Oncology 14745488 Elsevier Inc.
    The Lancet Oncology 14745488 Unknown
    The Lancet Oncology 1474-5488 Elsevier Inc.
    The Lancet Oncology 14702045 Elsevier Inc.
    The Lancet Oncology 14702045 Unknown
    The Lancet Oncology 1470-2045 Elsevier Inc.
    The Lancet. Oncology 1474-5488 Unknown
    The Lancet. Oncology 14745488 Unknown
    Unknown (1470-2045) 1470-2045 Unknown